ORIGINAL ARTICLE

The whole genome sequencing of *Acinetobacter-calcoaceticus-baumannii complex* strains involved in suspected outbreak in an Intensive Care Unit of a pediatric hospital

Elisabetta Ugolotti, Eddi Di Marco, Roberto Bandettini, Gino Tripodi, Roberto Biassoni*

Istituto Giannina Gaslini, Genova, Italy

Received: July 6, 2016 **Accepted:** August 19, 2016 **Online Published:** October 27, 2016
DOI: 10.5430/jha.v5n6p81 **URL:** http://dx.doi.org/10.5430/jha.v5n6p81

ABSTRACT

Background: To analyze the genetic characteristics of *Acinetobacter-calcoaceticus-baumannii complex* strains isolated in suspected outbreak in a Intensive Care Unit of a pediatric hospital in order to promptly stop the dissemination of this dangerous strain.
Methods: This study described the use of whole genome obtained by Next Generation Sequencing to define the clonality of 13 *Acinetobacter-calcoaceticus-baumannii complex* strains and to study their Resistoma. This was required because *Acinetobacter baumannii* is known to be resistant to desiccation and to disinfectants and is difficult to treat and eradicate. Thus, this microorganism is a major problem that demands a rigorous outbreak monitoring program to prevent and control the spread of the dangerous strain.
Results: The first result of our analysis has been to describe precisely the characteristics of isolates involved in the nosocomial infection, reduce the dimension of the more problematic isolates sustaining the outbreak and promptly facilitate the control of the strains diffusion. Indeed, our study indicated that among the 13 *Acinetobacter baumannii-calcoacteticus complex* strains, identified by biochemical and mass-spectrometry assays, 7 were *Acinetobacter baumannii*, 5 were *Acinetobacter calcoaceticus*, and one was Acinetobacter haemolyticus. The analysis of clonality of *Acinetobacter baumannii* indicated that three strains of ST744 were identical for > 99.8% among them and thus have sustained an outbreak in Intensive Care Unit. All personnel and possible environment samples were also monitored and all the procedures aimed to the prevention and control of Hospital Acquired Infections (HAI), have been strictly enforced by the Hospital Infection Control Committee. This gave the possibility to trace a strain from an environmental contamination characterized by high degree of clonality with the one isolated from a patient. On the contrary *Acinetobacter calcoaceticus* strains were different from each other and thus they were not responsible for any outbreak. The Resistoma analysis indicated a correspondence between phenotypic and genotypic characteristics of analyzed strains.
Conclusions: Next Generation Sequencing is an appropriate technique to trace the circulation of dangerous strains sustaining nosocomial infections. The combination of the high resolution genotyping together with the definition of the antibiotic genetic determinants and the precise species identification make this technique a useful tool employed as standard practice to control HAI.

Key Words: *Acinetobacter baumannii*, Whole genome sequencing, Pediatric hospital outbreak, Resistoma

*Correspondence: Roberto Biassoni; Email: robertobiassoni@gaslini.org; Address: Istituto Giannina Gaslini, Genoa, 16147, Italy.

1. INTRODUCTION

The identification of Acinetobacter species by phenotypic methods or simple mass-spectrometry gives ambiguous definition so that these microrganisms are often referred as *Acinetobacter-calcoaceticus-baumannii complex*.[1,2] *Acinetobacter baumannii* certainly plays a major role as an opportunistic pathogen mainly involved in nosocomial infections, while Acinetobacter calcoaceticus is often recovered from the environment and is hardly implicated in serious clinical disease. Indeed, *Acinetobacter baumannii* is recovered in ventilator-associated pneumonia, catheter-related and wound infections particularly in patients admitted in UTI-Intensive Care Unit (UTI).[3–6] Furthermore, it is intrinsically resistant to many antimicrobial agents and frequently acquires genetic elements conferring multi-drug resistance (MDR).[7–9] *Acinetobacter baumannii* is resistant to desiccation and to disinfectants, it is difficult to be treated and to be eradicated and it requires rigorous monitoring programs to prevent and control hospital outbreaks.[10]

Guidance documents[11–13] on the control of Acinetobacter baumannii nosocomial infections are based on the combined interventions including an active microbiological surveillance, precautions to contain the spread of infections from patient to patient and nursing care protocols for colonized patients. Additional measures regard: antibiotic use restriction, careful hand hygiene, extensive environmental surface decontamination procedures[14] and clinical staff education on how to deal with an outbreak. In particular, a careful examination to search any possible environmental contaminated surfaces around the patient by a precise cultural screening will be performed; adequate cleaning and disinfection of the hospital room, including furniture with special attention to rough handling points such as door handles, faucets and patient units are necessary. All these procedures are required to ensure a proper infection control and in case of suspected outbreaks they must be enforced as soon as possible.[15] Therefore, hospital acquired infection (HAI) investigations are often triggered by laboratory-based surveillance programs to identify an increase of Acinetobacter baumannii infections, a cluster of infected patients, or a new strain with an atypical susceptibility profile.[16]

To trace HAI it is necessary to use the best high resolution typing approach that unequivocally identifies Acinetobacter species and their clonality, in order to search for the index case and to define the strains relatedness to avoid nosocomial cross transmission.[17–19] This study described the use of whole genome sequencing (WGS) by Ion Torrent Personal Genome Machine to analyze Acinetobacter-calcoaceticus-baumannii complex strains isolated in a possible outbreak occurring in a Intensive Care Unit of a pediatric hospital. De novo assembled sequences from 13 strains were analyzed to define strains clonality and Resistoma. The high resolution genotyping, the definition of antibiotic genetic determinants, and the precise species identification make WGS an appropriate technique to be used as standard practice in hospitals in order to trace the circulation of dangerous MDR strains.

2. METHODS

2.1 Bacterial strains

We analyzed 13 non-duplicated bacteria identified according to conventional phenotypic methods as Acinetobacter-calcoaceticus-baumannii complex. They were isolated from 12 different pediatric patients and from one environmental contamination. Eight of these were from patients admitted to UTI-Intensive Care Unit (UTI) from June 24th to July 29th and suspected to have sustained possible outbreak. Two isolates, used as controls, were recovered in the same period from Orthopedic and Pneumology units. The last three strains originated from Neonatal Intensive Care Unit (CNR) in a restricted period close to the previous one (August-September 2015) were also suspected to have originated another outbreak.

Isolates were collected from blood, bronchoalveolar-lavage and upper airways specimens.

Phenotypic identifications were carried out by semi-automated Phoenix system and confirmed by Mass spectrometry microbial identification system Vitek MS (BioMerieux). Antimicrobial susceptibility was made by broth micro-dilution and Minimum inhibitory concentration (MIC) for Amikacin (AK), Gentamicin (GM), Tobramycin (TO), Ciprofloxacin (CIP), Levofloxacin (Levo), Imipenem (IMP), Meropenem (MEM), Colistin (Coli) and trimethoprim sulfamethoxazole (SXT) were determined following The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendation and interpretations.[7]

All the procedures aimed at the prevention and control of HAI were strictly enforced by the Hospital Infection Control Committee. The microbiological monitoring in active surveillance was carried out by preventive rectal swab screening of any patients admitted to the hospital in order to know the presence of the dangerous strain and to prevent its spread. During the emerging outbreak we also implemented pro-active measure such as rectal swab screening performed at regular time intervals on all patients and on all their possible contacts in the incriminated ward (UTI). In particular, patients have been screened twice a week for microbiological sentinel events (rectal-, nasal-swabs and broncho-alveolar-lavage) and all personnel (nasal- and throat-swab) and possible environment samples (swabs and/or fluid of various surface) were also

microbiologically monitored in the same period.

2.2 Genome sequencing

DNA of each strain was extracted using the Magtration System 12GC plus (Precision System Science USA, Inc) according to the manufacturer's instruction and used for library preparation.

DNA libraries were obtained starting from 200 ng of genomic DNA using enzymatic shearing and size-selection (Pippin Prep SAGE SCIENCE) in order to obtain a median library fragments of 470 bp (mean of library size 400 bp + adaptor 70 bp). The libraries size and quality were checked using DNA High-Sensitivity Kit and the Bioanalyzer-2100 (Agilent Technologies, CA, USA) and the mean size of the library was 491 bp with a coefficient of variation of 9%, while concentrations were evaluated by Qubit dsDNA HS-Assay Kit (Invitrogen). The templates preparation were carried out using the Ion PGM HiQ-OT2 following the manufacturer's instruction. DNA sequences were obtained by Ion Torrent PGM (Thermo Fisher Scientific) using Ion PGM HiQ Sequencing Kit (Thermo Fisher Scientific) and Ion 316v2 chips (Thermo Fisher Scientific). The sequenced samples give a mean of 413,517 reads (from 689,863 to 208,895 reads) with a standard deviation of 140,946 reads.

2.3 Bioinformatic analyses

The obtained WGS reads have been de novo assembled using SPAdes v3.1.0.[20] After the assembly procedure, we got a mean of 307 contigs (from 455 to 152) with 100 as standard deviation. The mean size of them was 14,452 base pairs (from 26,073 to 8,861). More in detail, the mean size of the higher assembled fragment was 336,625 bp (from 50,8859 to 201,190) with a Standard deviation of 96,532, while the mean of the lower length fragment size was 103 (from 108 to 103) with a Standard deviation of 2. The relative contigs have been referred to microbial genomes of the NCBI database to identify the strain species. Analysis of each genome has been performed either on the SeqSphere software v3.0 (Ridom) or using in house prepared databases working on CLC-BIO server/CLC Genomic Workbech 6.5 suite (Qiagen).

Multilocus Sequence Typing (MLST) and clonality (extended-MLST) were carried out using Ridom SeqSphere software v3.0 (Ridom) and the Sequence Type (ST) was assigned following the Oxford MLST gene profile (http://pubmlst.org/abaumannii/).

To define the genetic distance among isolates we first run the extended-MLST Target Definer routine of SeqSphere suite. Thus using as reference the annotated Genomes of the *Acinetobacter baumannii* ATCC-17978 (CP000521) or the Acinetobacter calcoaceticus PHEA-2 (CP002177) and genomes present in the database, we have define the core number of genes used to study the clonality of *Acinetobacter baumannii* (1,701 gene alleles) and Acinetobacter calcoaceticus (985 genes).

2.4 Resistome analysis

The assembled contigs for each bacterial genome were blasted against the listed databases: Resistance Determinants DataBase (RED-DB) (http://www.fibim.unisi.it/REDDB/), Center for Genomic Epidemiology ResFinder2.1 (https://cge.cbs.dtu.dk/services/ResFinder/), CARD Resistance Gene Identifier-v2.0 (http://arpcard.mcmaster.ca/), ARG-ANNOT Mutional Gene DB (http://en.mediterranee-infection.com/article.php?laref=283%26titre=arg-annot-).[21] More in detail, RED-DB, ARG-ANNOT and PmrA, PmrB, mcr-1 (Polymixin antibiotic resistance) gene sequences have been used to prepare in-house databases. The first three databases have been used to search for genes conferring resistance, while the latter was used to look for point mutations.

3. Results

3.1 Epidemiology

This is the first observed outbreak sustained by *Acinetobacter baumannii* observed in our hospital. During the period in observation, we found an increase of colonized/infected patients by Acinetobacter-baumannii-calcoaceticus complex admitted in UTI. Indeed the rate of colonized/infected patients in that ward respect to the all the hospital was of 29.4% (5 UTI patients out of 17 hospital patients) in 2013 and 33% (4 out of 12) in 2014. The rate increased up to 56.2% (9 out of 16) in 2015 and went back to the registered ward/hospital average, since in the first trimester 2016 we observed a rate of 33% colonized/infected patients (1 out of 3). It is to be stressed that the majority of *Acinetobacter baumannii* colonized/infected patients in 2015 have been concentrated in a one month period (June-July 2015).

3.2 Clonal analysis

The first result of our WGS analysis was a correct species identification of 13 *Acinetobacter-baumannii-calcoacteticus complex* isolates suspected to sustain nosocomial outbreaks in a one month period of time in the summer of 2015. We defined the strains as suspected outbreak, because isolated frequently in a short period of time (one month) in the same ward.

Thus, the assembled genomes were compared to the microbial sequences database by Basic Local Alignment Search Tool (blast), in order to define Acinetobacter species, since the phenotypic analysis identified only the complex. Our

study indicated that among the 13 *Acinetobacter-baumannii-calcoaceticus complex* only 7 belong to the *Acinetobacter baumannii* specie, while the other 5 were classified *Acinetobacter calcoaceticus*, and one *Acinetobacter haemolyticus*.

Indeed the precise species identification gave us the possibility to divide our outbreak analysis between the *Acinetobacter baumannii* and *Acinetobacter calcoaceticus*, decreasing the alarm about the possible spread of the more virulent dangerous MDR-resistant *Acinetobacter baumannii* isolates. We analyzed strain clonality using extended-MLST the Neighbor-Joining phylogenetic tree and Minumum Spanning Tree for *Acinetobacter baumannii/Acinetobacter calcoacetices* were obtained analyzing 1,701 and 985 gene respectively, as reported in Figures 1 and 2. Using the above reported data we could also define the MLST for *Acinetobacter baumannii* revealing that three isolates were ST744, two ST195 and one ST281, while the last strain (contig_47) was not yet definable on the basis of available MLST databases (ST-ND). For *Acinetobacter calcoaceticus* the ST could not be defined since alleles for some gene loci have not been reported, yet.

Our analysis using extended-MLST indicated that three strains (contig_34, _35 and _48) were clonal. Indeed the ST744 *Acinetobacter baumannii* differed for one or two alleles on 1,701 studied genes (> 99.8% of identity) and sustained an outbreak in UTI (see Figure 1).



Sample ID	Distance N alleles	Distance %	MLST
Contig_48_UTI			ST744
Contig_34_UTI	1	0.1	ST744
Contig_35_UTI	2	0.2	ST744
Contig_37_UTI	1569	92.8	ST281
Contig_38_UTI	1572	93.0	ST195
Contig_36_UTI	1573	92.9	ST195
Contig_47_CNR	1572	92.7	

Sample ID	Distance N alleles	Distance %	MLST
Contig_48_UTI	1573	92.9	ST744
Contig_34_UTI	1573	93.0	ST744
Contig_35_UTI	1573	92.9	ST744
Contig_37_UTI	317	18.9	ST281
Contig_38_UTI	2	0.2	ST195
Contig_36_UTI			ST195
Contig_47_CNR	1588	93.6	

Figure 1. Philogenetic tree and comparison tables of Acinetobacter baumannii strains evaluated on 1701 genes
A: Neighbor-Joining tree shows the phylogenetic distance among the 7 strains; B: Minumum Spanning Tree is drawn for the analyzed strains indicating the distances in term of number of different alleles separating them. C and D: Comparison table with allelic distance as number of allelic differences or % was calculated using as reference sequence from the ST744 Contig_48 (panel C) or the ST195 Contig_36 (panel D), respectively.

In addition, we indentified an environment contamination since the two ST195 strains, isolated from a patient (contig_36) and from the room door handle (contig_38), resulted 99.8% identical (see Figure 1). The ST281 (contig_37) recovered from UTI was not be related to the other *Acinetobacter baumannii* UTI-strains.

The molecular analysis of suspected CNR strains indicated that only one was *Acinetobacter baumannii* (ST-ND, Contig_47) unrelated to all the other and thus not relevant. In addition, the other two CNR strains resulted *Acinetobacter calcoaceticus* (contig_45 and _46), they were not related each other and were different from the other UTI *Acinetobacter calcoaceticus* strains showing allelic differences higher than 31% (see Figure 2).



Figure 2. Philogenetic tree and comparison tables of *Acinetobacter calcoaceticus* evaluated on 985 genes
A: Neighbor-Joining tree shows the phylogenetic distance among the 5 strains; B: Minumum Spanning Tree is drawn for the analyzed strains indicating the distances in term of number of different alleles separating them. C-E: Comparison table with allelic distance as number of allelic differences or % was calculated using as reference sequence from the Contig_41 (panel C), Contig_33 (Panel D) and Contig_39 (Panel E), respectively.

Table 1. Acinetobacter baumannii antibiotic susceptibility

Antibiotic		**ST744**		**ST195**		**ST281**		**ST-ND**	
class	Type	phenotypic	Resistoma	phenotypic	Resistoma	phenotypic	Resistoma	phenotypic	Resistoma
Aminoglycosides	AK GM TO	8 S > 4 R 4 S	*porin D*	> 16 R > 4 R > 4 R	*aph(3'')-Ib, aph(3')-Ic, aph(6), armA*	> 16 R > 4 > 4 R	*aph(3'')-Ib, aph(3')-Ic, aph(6), armA, aadA1*	4 S ≤ 1 S 4 S	No Resistance
Beta-lactams	IMP MEM	≤ 1 S 0.5 S	*blaOXA-51*no ISAba1, *bla-ADC** no ISAba1	> 8 R > 8 R	*blaOXA-66/ISAba1, blaOXA-23/ISAba1, blaADC-25/ISAba1, AmpC-like/ISAba1, blaTEM-19*	> 8R > 8 R	*blaOXA-66/ISAba1, blaOXA-23/ISAba1, blaADC-25/ISAba1, AmpC-like/ISAba1*	≤ 1 S 0.5 S	*blaOXA-120* no *ISAba1*, *blaADC* no *ISAba1*
Quinolones	CIP LEVO	1 S ≤ 0.5 S	No Resistance	> 1 R > 2 R	GyrA-S83L, ParC-S80K	> 1 R > 2 R	GyrA-S83L, ParC-S80K	≤ 0.5 S ≤ 0.5 S	No Resistance
Polymyxine	COLI	≤ 1S	*PmrB*-L237M, *PmrB*-N440H, *lpxD*-R57C, *lpxD*-K117E, *lpxD*-K356E	≤ 1 S	*PmrB*-P170L, *PmrB*-N440H, *PmrB*-A444V	≤ 1 S	*PmrB*-P188T, *PmrB*-N440H, *PmrB*-A444V	≤ 1 S	*PmrB*-N440H, *lpxD*-V63I, *lpxD*-K117E, *lpxD*-G166S
Sulphonamides	SXT	≤ 1/19 S	No Resistance	> 4/76 R	*sul2*	> 4/76 R	*sul1*	≤ 1/19 S	No Resistance

*Preliminary Stop codon; AK = amikacin; GM = Gentamicin; TO = Tobramicin; IMP = Imipenem; MEM = Meropenem; CIP = Ciprofloxacin; LEVO = Levofloxacin; COLI = Colistin; and SXT = trimethoprim sulfamethoxazole; The phenotypic antimicrobial susceptibility: S = sensitive; R = Resistant

3.3 Antimicrobial susceptibility

The phenotypic antimicrobial susceptibility is shown in Table 1.

3.4 Resistoma

The analysis of aminoglycosides resistance in our survey indicated that ST195 isolates carry the genetic determinants aph(3")-Ib, aph(3')-Ic, aph(6)-Id[22] and armA 16S-RNA-methylase[23] and ST281 presented the same genes showed above with the addition of aadA1. These genetic determinants explained the resistance to all the aminoglycosides tested AK, GM, TO. Finally the ST744 isolates do not present any gene coding for aminoglycosides resistance in accordance with the phenotypic test.

The beta lactams analysis revealed that, Acinetobacter baumannii ST195 and ST281 strains resulted phenotypically carbapenem resistant. Indeed, the genotype of these strains is characterized by the presence of blaADC, blaOXA-66 and blaOXA-23 all controlled by the upstream ISAba1 genetic element. Moreover, ST195 isolates have also blaTEM-19. The ST744 isolates are all sensitive to carbapenems and presented blaOXA-51-like gene and blaADC gene, but without the regulatory ISAba1 upstream sequences.

Resistance to quinolones is due to chromosomal mutation of GyrA and ParC gene[24,25] In our analysis only the strains ST195 and ST281 are characterized by these mutations and resulted ciprofloxacin and levofloxacin resistant. To analyze the genes responsible for Polymyxins resistance we investigated the presence of mutations in PmrA, PmrB and the lpxA, lpxC, lpxD genes.[26–31] Acinetobacter baumannii strains characterized by ST281, ST195, ST744 do not present any mutations for the PmrA, lpxA, lpxC genes. The analysis of PmrB gene showed that the ST281 presented 3 mutations (P188T, N440H, A444V), the ST744 had 2 mutations (L237M, N440H) and finally the ST195 displayed 3 mutations (P170L, N440H, A444V). Moreover, lpxD gene in ST744 showed R57C, K117E, K356E mutations. It is important to stress that these mutations have never been reported to induce polymyxins resistance in accordance to the phenotypic susceptibility tests (MIC $\leq$ 1 mg/ml).[18,19]

Sulfonamide resistance in gram-negative bacteria is dependent on genes encoding dihydropteroate-synthase sul1 and sul2.[32] In our analysis we found that both ST195 isolates are characterized by the sul2 sulphonamide resistance determinant, while the ST281 strain presented the sul1 gene. These data explain the Trimethoprim/sulfamethoxazole (SXT) phenotypical resistance present only in MDR strains (see Table 1).

Regarding the last Acinetobacter baumannii strain (ST-ND) studied, no genetic determinants have been found for any antibiotic as expected by phenotypic assays. Genetic analysis of quinolones resistance gene has only revealed mutations not associated, until now, with antibiotic resistance thus in accordance to phenotypic data.[24,25] In addition, the presence of beta-lactams resistance gene (see Table 1), lacking for ISAba1 elements involved in the transcriptional regulation, explained the phenotypic sensitivity.

4. DISCUSSION AND CONCLUSIONS

Our study described the monitoring of suspected outbreak sustained by *Acinetobacter-baumannii-calcoacteticus complex* occurred in a pediatric setting analyzing whole bacterial genome by NGS technology (Ion-Torrent platform). The use of this technology has been previously validated in a case of MRSA pediatric outbreaks making NGS a useful tool in HAI investigation.[33] The need to perform a precise genetic strain characterization was determined by the observation of the doubling of patients infected with *Acinetobacter-baumannii-calcoacteticus complex* in a short observation period. Such necessity was burdened by the fact that this was the first case of suspected outbreak supported by *Acinetobacter-baumannii-calcoacteticus complex* in our hospital. The first important result obtained by NGS-analysis revealed that among the 13 *Acinetobacter-baumannii-calcoacteticus complex* isolates only 7 were *Acinetobacter baumannii*, thus reducing the dimension of the hypothetical outbreak. Indeed, the correct species identification obtained by sequence analysis revealed and overcame the deficiencies of phenotypic identification methods. It is to be stressed that among the *Acinetobacter baumannii*, 5 strains could be defined as MDR, in accordance with the criteria of the Centers for Disease Control and Prevention (CDC), since they showed resistance to fluoroquinolones, amynoglycosides, carbapenems.[34] In addition, one of these MDR strains was isolated from an environmental specimen in ICU. The study of the *Acinetobacter baumannii* clonality revealed that three of them (ST744) sustained an outbreak because they were at least 99.8% identical, analyzing 1,701 gene loci. Fortunately, these isolates resulted to be sensitive to all the tested antibiotics (aminoglycosides, carbapenems, quinolones, polymyxins, Trimethoprim/sulfamethoxazole) and thus they could easily be treated avoiding any further outbreak expansion.

Finally, the analysis of MDR ST195 strains (Contig_36 and _38, coming from a patient and a door-handle respectively), underlining that they were 99.8% identical based on 1,701 genes analyzed, showed how an environmental contamination can be a possible source of nosocomial infection spread. This prompt information, strictly enforced by the Hospital Infection Control Committee, was important to begin in real

time the successive strategy of containment and to block dangerous strain circulation. Indeed, thank to this survey in the first trimester 2016 the percentage of infected patients has been lowered to 30% that has been the normal rate registered in the previous years.

The strain ST281 despite its MDR resulted to be different for 317 out of 1,701 (18.9%) of the gene loci analyzed and did not spread to other patients. Thus, our data indicate that NGS used for the microbial whole gene sequencing allowed us to understand at a finer level, the dynamic of strain transmission within the hospital in a restricted period of time giving us the opportunity to define a real single outbreak.

It is known that today WGS gives more information than any other assay for molecular characterization of strains involved in an outbreak making its use ideal in local epidemiological analysis. In addition, the sequencing of the whole microbial genome is used to study not only the presence of resistance genes, but also mutations involved in the mechanism of antimicrobial resistance and it gives information regarding the regulation of gene expression Indeed, by our analysis we found a strict correlation between phenotypic and genotypic data for antibiotic resistance, emphasizing the role of the ISAba1 sequences, which are strong promoters necessary for gene expression of beta-lactamases.[35–37] All Acinetobacter baumannii have the blaADC gene, but only the ST195 and ST281 strains are characterized by the upstream Insertion Sequences (IS) genetic element ISAba1, that determines the overexpression of blaADC gene responsible for resistance to extended spectrum cephalosporines (ESBL).[35,36] In addition among the ESBLs identified in Acinetobacter baumannii we have to consider the class A beta-lactamases encoded by the blaTEM gene[38] and more importantly, the class D beta-lactamases encoded by blaOxa genes. Also the latter genes are regulated by upstream IS genetic (ISAba) elements decisive for the resistance to carbapenems.[37,39,40] It is of note that only in ST195 and ST281 isolates we have found blaOxa-66 and blaOxa-23 regulated by IS genetic elements and also the blaTEM-19. It is to be stressed that blaOXA-23 gene encodes the most prevalent and endemic carbapenemase in Italy.[41] Regarding the analysis of polymixins, all the strains analyzed had a phenotypic susceptibility that correlate with the absence of a specific genetic determinant except PmrB-P170L[26,28] in ST195 strain, that in a single report was indicated as responsible for a possible resistant mechanism.[16] In general, our genetic data confirmed the phenotypic susceptibility test objectively supporting the antibiotic therapies adopted by clinicians.

In conclusion, WGS is a fundamental tool in the active surveillance of an outbreak. It will be included in standard prevention and control of infection spread in order to help Hospital Infection Control Committees to trace circulation of dangerous strains and to study their epidemiological aspect.

CONFLICTS OF INTEREST DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

[1] Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol. 1991; 29: 277-282. PMid: 2007635.

[2] Koh TH, Tan TT, Khoo CT, et al. *Acinetobacter calcoaceticus-Acinetobacter baumannii complex* species in clinical specimens in Singapore. Epidemiol Infect. 2012; 140: 535-538. PMid: 21733253. http://dx.doi.org/10.1017/S0950268811001129

[3] Ansaldi F, Canepa P, Bassetti M, et al. Sequential outbreaks of multidrug-resistant *Acinetobacter baumannii* in intensive care units of a tertiary referral hospital in Italy: combined molecular approach for epidemiological investigation. J Hosp Infect. 2011; 79: 134-140. PMid: 21820758. http://dx.doi.org/10.1016/j.jhin.2011.05.027

[4] Shelburne SA, Singh KV, White AC, et al. Sequential outbreaks of infections by distinct *Acinetobacter baumannii* strains in a public teaching hospital in Houston, Texas. J Clin Microbiol. 2008; 46: 198-205. PMid: 18003801. http://dx.doi.org/10.1128/JCM.01459-07

[5] Zarrilli R, Crispino M, Bagattini M, et al. Molecular epidemiology of sequential outbreaks of *Acinetobacter baumannii* in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol. 2004; 42: 946-953. PMid: 15004037. http://dx.doi.org/10.1128/JCM.42.3.946-953.2004

[6] McGrath EJ, Chopra T, Abdel-Haq N, et al. An outbreak of carbapenem-resistant *Acinetobacter baumannii* infection in a neonatal intensive care unit: investigation and control. Infect Control Hosp Epidemiol. 2011; 32: 34-41. PMid: 21091204. http://dx.doi.org/10.1086/657669

[7] Available from: http://www.eucast.org/expert.rules/

[8] Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21: 538-82. PMid: 18625687. http://dx.doi.org/10.1128/CMR.00058-07

[9] Alvargonzalez JJ, Vindel Hernando A, Martín MD, et al. Sequential outbreaks in a Spanish hospital caused by multiresistant OXA-58-producing *Acinetobacter baumannii* ST92. J Med Microbiol. 2014; 63: 1093-1098. PMid: 24866368. http://dx.doi.org/10.1099/jmm.0.067280-0

[10] Salipante SJ, SenGupta DJ, Cummings LA, et al. Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology. J Clin Microbiol. 2015; 53: 1072-1079. PMid: 25631811. http://dx.doi.org/10.1128/JCM.03385-14

[11] European Centre for Disease Prevention and Control. Risk assessment on the spread of carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare facilities, with special emphasis on cross-border transfer. Stockholm: ECDC; 2011.

[12] Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR. 2009; 58: 256-260. PMid: 19300408.

[13] Grundmann H, Livermore DM, Giske CG, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill. 2010. PMid: 21144429.

[14] Otter JA, Yezli S, French GL. The role played by contaminated surfaces in the transmission of nosocomial pathogens. Infect Control Hosp Epidemiol. 2011; 32: 687-699. PMid: 21666400. http://dx.doi.org/10.1086/660363

[15] Akova M, Daikos GL, Tzouvelekis L, et al. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012; 18: 439-48. PMid: 22507111. http://dx.doi.org/10.1111/j.1469-0691.2012.03823.x

[16] Sabat AJ, Budimir A, Nashev D, et al. Overview of molecular typing methods for outbreak detection and epidemiological surveillance. Euro Surveill. 2013; 18.

[17] Alshahni MM, Asahara M, Kawakami S, et al. Genotyping of *Acinetobacter baumannii* strains isolated at a Japanese hospital over five years using targeted next-generation sequencing. J. Infect Chemother. 2015; 21: 512-5. PMid: 25862195. http://dx.doi.org/10.1016/j.jiac.2015.03.009

[18] Kanamori H, Parobek CM, Weber DJ, et al. Next-Generation Sequencing and Comparative Analysis of Sequential Outbreaks Caused by Multidrug-Resistant *Acinetobacter baumannii* at a Large Academic Burn Center. Antimicrob Agents Chemother. 2015; 60: 1249-57. PMid: 26643351. http://dx.doi.org/10.1128/AAC.02014-15

[19] Lewis T, Loman NJ, Bingle L, et al. High-throughput whole-genome sequencing to dissect the epidemiology of *Acinetobacter baumannii* isolates from a hospital outbreak. J Hosp Infect. 2010; 75: 3-41. PMid: 20299126. http://dx.doi.org/10.1016/j.jhin.2010.01.012

[20] Bankevich A, Nurk S, Antipov D, et al, Journal of Computational Biology. 2012; 19: 455-477. PMid: 22506599. http://dx.doi.org/10.1089/cmb.2012.0021

[21] Gupta SK, Padmanabhan BR, Diene SM, et al. Antimicrobial Agents and Chemother. 2014; 58: 212-220. PMid: 24145532. http://dx.doi.org/10.1128/AAC.01310-13

[22] Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat. 2010; 13: 151-171. PMid: 20833577. http://dx.doi.org/10.1016/j.drup.2010.08.003

[23] Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis. 2007; 45: 88-94. PMid: 17554708. http://dx.doi.org/10.1086/518605

[24] Gu DX, Hu YJ, Zhou HW, et al. Substitutions of Ser83Leu in GyrA and Ser80Leu in ParC Associated with Quinolone Resistance in *Acinetobacter pittii*. Microb Drug Resist. 2015; 21: 345-351. PMid: 25514581. http://dx.doi.org/10.1089/mdr.2014.0057

[25] Vila J, Ruiz J, Goni P, et al. Mutation in the gyrA gene of quinolone-resistant clinical isolates of *Acinetobacter baumannii*. Antimicrob Agents Chemother. 1995; 39: 1201-1203. PMid: 7625818. http://dx.doi.org/10.1128/AAC.39.5.1201

[26] Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014; 5: 64. PMid: 25505462. http://dx.doi.org/10.3389/fmicb.2014.00643

[27] Pournaras S, Poulou A, Dafopoulou K, et al. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in *Acinetobacter baumannii*. Antimicrob. Agents Chemother. 2014; 58: 828-832. PMid: 24247145. http://dx.doi.org/10.1128/AAC.01439-13

[28] Arroyo LA, Herrera CM, Fernandez L, et al. The pmrCAB operon mediates polymyxin resistance in *Acinetobacter baumannii* ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob. Agents Chemother. 2011; 55: 3743-3751. PMid: 21646482. http://dx.doi.org/10.4103/1119-3077.104529

[29] Kim Y, Bae IK, Jeong SH, et al. In Vivo Selection of Pan-Drug Resistant *Acinetobacter baumannii* during Antibiotic Treatment. Yonsei Med J. 2015; 56: 928-934. PMid: 26069113. http://dx.doi.org/10.3349/ymj.2015.56.4.928

[30] Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in *Acinetobacter baumannii* is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 2010; 54: 4971-4977. PMid: 20855724. http://dx.doi.org/10.1128/AAC.00834-10

[31] Lean SS, Suhaili Z, Ismail S, et al. Prevalence and genetic characterization of carbapenem- and polymyxin-resistant *Acinetobacter baumannii*. Isolated from a tertiary hospital in Terengganu, Malaysia. ISRN Microbiol. 2014; 953417. PMid: 25006521.

[32] Nigro SJ, Hall RM. GIsul2, a genomic island carrying the sul2 sulphonamide resistance gene and the small mobile element CR2 found in the Enterobacter cloacae subspecies cloacae type strain ATCC 13047 from 1890, Shigella flexneri ATCC 700930 from 1954 and *Acinetobacter baumannii* ATCC 17978 from 1951. J Antimicrob Chemother. 2011; 66: 2175-2176. PMid: 21653606. http://dx.doi.org/10.1093/jac/dkr230

[33] Ugolotti E, Larghero P, Vanni I, et al. Whole Genome Sequence as standard practice for the analysis of clonality in Methicillin-resistant Staphyloccus aureus pediatric outbreak. J. Hospital Infection. 2016; 93: 375-381. PMid: 27184087. http://dx.doi.org/10.1016/j.jhin.2016.04.003

[34] Sievert DM, Ricks P, Edwards JR, et al. National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013; 34: 1-14. PMid: 23221186. http://dx.doi.org/10.1086/668770

[35] Ruiz M, Marti S, Fernandez-Cuenca F, et al. Prevalence of IS(Aba1) in pidemiologically unrelated *Acinetobacter baumannii* clinical isolates. FEMS Microbiol Lett. 2007; 274: 63-66. PMid: 17610514. http://dx.doi.org/10.1111/j.1574-6968.2007.00828.x

[36] Héritier C, Poirel L, Nordmann P. Cephalosporinase over-expression resulting from insertion of ISAba1 in *Acinetobacter baumannii*. Clin Microbiol Infect. 2006; 12: 123-130. PMid: 16441449. http://dx.doi.org/10.1111/j.1469-0691.2005.01320.x

[37] Turton JF, Ward ME, Woodford N, et al. The role of ISAba1 in expression of OXA carbapenemase genes in *Acinetobacter baumannii*. FEMS Microbiol Lett. 2006; 258: 72-77. PMid: 16630258. http://dx.doi.org/10.1111/j.1574-6968.2006.00195.x

[38] Krizova L, Poirel L, Nordmann P, et al. TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of *Acinetobacter baumannii*. J Antimicrob Chemother. 2013; 68: 2786-2791. PMid: 23838947. http://dx.doi.org/10.1093/jac/dkt275

[39] Karah N, Sundsfjord A, Towner K, et al. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of *Acinetobacter baumannii*. Drug Resist Updat. 2012; 15: 237-247. PMid: 22841809. http://dx.doi.org/10.1016/j.drup.2012.06.001

[40] Corvec S, Poirel L, Naas T, et al. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in *Acinetobacter baumannii*. Antimicrob Agents Chemother. 2007; 51: 1530-1533. PMid: 17220422. http://dx.doi.org/10.1128/AAC.01132-06

[41] Principe L, Piazza A, Giani T, et al. AMCLI-CRAb Survey Participants. Epidemic diffusion of OXA-23-producing *Acinetobacter baumannii* isolates in Italy: results of the first cross-sectional countrywide survey. J Clin Microbiol. 2014; 52: 3004-3010. PMid: 24920776. http://dx.doi.org/10.1128/JCM.00291-14